- Home
- CNTA
as 07-26-2024 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 994.8M | IPO Year: | 2021 |
| Target Price: | $11.00 | AVG Volume (30 days): | 263.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $12.45 | Next Earning Date: | 08-12-2024 |
| Revenue: | $6,853,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anderson Karen M. | CNTA | Chief People Officer | Mar 25 '24 | Sell | $11.66 | 29,995 | $349,624.72 | 92,690 | SEC Form 4 |
| Anderson Karen M. | CNTA | Chief People Officer | Mar 25 '24 | Sell | $12.21 | 21,165 | $258,335.76 | 71,525 | SEC Form 4 |
| Rotman Harris | CNTA | SVP Regulatory Affairs | Feb 1 '24 | Sell | $8.10 | 4,267 | $34,574.22 | 62,625 | SEC Form 4 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Oppenheimer Initiates Centessa Pharmaceuticals at Outperform Rating With $14 Price Target
Zacks
10 days ago
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
MT Newswires
a month ago
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $11 From $8, Maintains Equalweight Rating
MT Newswires
2 months ago
Centessa Pharmaceuticals Appoints John Crowley as CFO
GlobeNewswire
2 months ago
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
PR Newswire
2 months ago
3 Major Product Releases at 3Shape Discover Event
GlobeNewswire
2 months ago
Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens
GlobeNewswire
2 months ago
Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.